omeprazole has been researched along with simvastatin in 30 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (3.33) | 18.2507 |
| 2000's | 7 (23.33) | 29.6817 |
| 2010's | 19 (63.33) | 24.3611 |
| 2020's | 3 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Li, Y; Li, YH; Wang, YH; Yang, L; Yang, SL | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Artursson, P; Bergström, CA; Hoogstraate, J; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Chen, L; He, Z; Li, H; Liu, J; Liu, X; Sui, X; Sun, J; Wang, Y; Zhang, W | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
| Freiwald, S; Jiang, Y; Jones, JP; Kaspera, R; Katayama, J; Lee, CA; Smith, E; Totah, RA; Walker, GS | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Bharate, SS; Vishwakarma, RA | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Harvengt, C | 1 |
| Cairns, CP; Cohen, JP; Paquette, C | 1 |
| Cunningham, S; Hansford, D; John, D; McCaig, D; Stewart, D | 1 |
| Brandt, NJ; Stefanacci, RG | 1 |
| Abdu, S; Abuelkhair, M; Fahmy, S; Godman, B; Gustafsson, LL; Malmström, RE | 1 |
| Bennie, M; Bishop, I; Campbell, S; Godman, B | 1 |
| Abid, A; Abu-Elheja, O; Diab, H; Mahamid, M; Mograbi, J; Nseir, W; Samara, M | 1 |
| Ammori, BJ; Ashcroft, DM; Darwich, AS; Jamei, M; Pade, D; Rostami-Hodjegan, A | 1 |
| Burcharth, J; Eriksson, A; Rosenberg, J | 1 |
| Beutels, P; De Loof, H; Fraeyman, J; Hens, N; Van Hal, G; Verbelen, M | 1 |
| Cha, GS; Choi, DS; Jeong, KJ; Lee, JH; Lee, JK; Lee, SH; Nam, DH; Park, CB; Park, JH; Yun, CH | 1 |
| Becker, E; Bohrer, D; Carvalho, LM; Mattiazzi, P; Nascimento, PC; Viana, C | 1 |
| Ducray, PS; Endo-Tsukude, C; Gardner, I; Gill, KL; Hatley, OJ; Machavaram, KK; Parrott, N; Terao, K | 1 |
| d'Auriol, M; de Souza Santos, LV; Jacob, RS; Lange, LC; Lebron, YAR; Moreira, VR | 1 |
| Glick, A; Johnson, C; Sista, V | 1 |
| Kassie, GM; Kerr, M; Moffat, A; Pratt, N; Roughead, EE | 1 |
2 review(s) available for omeprazole and simvastatin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
[It is impossible to get information on the components of drugs that are derived from animals].
Topics: Access to Information; Animals; Chemistry, Pharmaceutical; Disclosure; Humans; Informed Consent; Medication Adherence; Omeprazole; Pharmaceutical Preparations; Religion and Medicine; Simvastatin | 2013 |
1 trial(s) available for omeprazole and simvastatin
| Article | Year |
|---|---|
Randomised clinical trial: simvastatin as adjuvant therapy improves significantly the Helicobacter pylori eradication rate--a placebo-controlled study.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Double-Blind Method; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Omeprazole; Proton Pump Inhibitors; Simvastatin; Treatment Outcome | 2012 |
27 other study(ies) available for omeprazole and simvastatin
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Modeling K(m) values using electrotopological state: substrates for cytochrome P450 3A4-mediated metabolism.
Topics: Computational Biology; Cyclohexanols; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Molecular Structure; Principal Component Analysis; Pyrrolizidine Alkaloids; Quantitative Structure-Activity Relationship; Reproducibility of Results; Substrate Specificity; Venlafaxine Hydrochloride | 2005 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antipsychotic Agents; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Cell Line; Computer Simulation; Cytochrome P-450 Enzyme System; Drug-Related Side Effects and Adverse Reactions; Estradiol; Humans; Insecta; Liver; Models, Molecular; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Pharmaceutical Preparations; Pharmacology; Structure-Activity Relationship | 2008 |
Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
Topics: Blood Proteins; Chemistry, Physical; Computer Simulation; Humans; Membranes, Artificial; Models, Biological; Pharmaceutical Preparations; Protein Binding; Tissue Distribution | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
Identifying a selective substrate and inhibitor pair for the evaluation of CYP2J2 activity.
Topics: Amiodarone; Astemizole; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP2J2; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Danazol; Drug Discovery; Drug Interactions; Enzyme Inhibitors; Humans; Hydroxylation; In Vitro Techniques; Methylation; Microsomes, Liver; Models, Biological; Molecular Structure; Substrate Specificity; Tandem Mass Spectrometry; Terfenadine | 2012 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Thermodynamic equilibrium solubility measurements in simulated fluids by 96-well plate method in early drug discovery.
Topics: Drug Discovery; Pharmaceutical Preparations; Solubility; Thermodynamics | 2015 |
Drugs recently released in Belgium. Omeprazole--simvastatin.
Topics: Anticholesteremic Agents; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Omeprazole; Simvastatin | 1990 |
Switching prescription drugs to over the counter.
Topics: Drug Prescriptions; Europe; Legislation, Drug; Loratadine; Nonprescription Drugs; Omeprazole; Self Care; Simvastatin; United States | 2005 |
A comparison of community pharmacists' views of over-the-counter omeprazole and simvastatin.
Topics: Anticholesteremic Agents; Attitude of Health Personnel; Community Pharmacy Services; Dyspepsia; Humans; Nonprescription Drugs; Omeprazole; Patient Compliance; Patient Participation; Pharmacists; Professional Competence; Risk Assessment; Self Care; Simvastatin; Surveys and Questionnaires; United Kingdom | 2007 |
Discontinuation of unnecessary medications in older adults.
Topics: Aged; Aged, 80 and over; Alendronate; Anti-Ulcer Agents; Antihypertensive Agents; Assisted Living Facilities; Bone Density Conservation Agents; Case Management; Diabetes Mellitus; Drug Therapy; Evidence-Based Medicine; Guidelines as Topic; Hepatitis; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Lisinopril; Longevity; Male; Omeprazole; Osteoporosis; Palliative Care; Pharmacists; Precision Medicine; Simvastatin | 2011 |
Imperative to consider multiple initiatives to maximize prescribing efficiency from generic availability: case history from Abu Dhabi.
Topics: Drugs, Generic; Health Policy; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insurance, Health, Reimbursement; Insurance, Pharmaceutical Services; Omeprazole; Patents as Topic; Practice Patterns, Physicians'; Proton Pump Inhibitors; Simvastatin; United Arab Emirates | 2012 |
Multiple initiatives continue to enhance the prescribing efficiency for the proton pump inhibitors and statins in Scotland.
Topics: Atorvastatin; Drugs, Generic; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insurance, Health, Reimbursement; Insurance, Pharmaceutical Services; Omeprazole; Practice Patterns, Physicians'; Proton Pump Inhibitors; Pyrroles; Scotland; Simvastatin | 2012 |
A mechanistic pharmacokinetic model to assess modified oral drug bioavailability post bariatric surgery in morbidly obese patients: interplay between CYP3A gut wall metabolism, permeability and dissolution.
Topics: Administration, Oral; Bariatric Surgery; Biological Availability; Chemistry, Pharmaceutical; Ciprofloxacin; Computer Simulation; Cytochrome P-450 CYP3A; Diclofenac; Fluconazole; Humans; Intestinal Mucosa; Models, Biological; Obesity, Morbid; Omeprazole; Permeability; Pharmaceutical Preparations; Simvastatin; Solubility | 2012 |
Evolutions in both co-payment and generic market share for common medication in the Belgian reference pricing system.
Topics: Belgium; Cost Sharing; Drug Costs; Drugs, Generic; Histamine H2 Antagonists; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insurance, Pharmaceutical Services; Omeprazole; Proton Pump Inhibitors; Simvastatin | 2013 |
Cofactor-free light-driven whole-cell cytochrome P450 catalysis.
Topics: Bacterial Proteins; Biocatalysis; Cytochrome P-450 Enzyme System; Electron Transport; Escherichia coli; Estradiol; Fluorescein; Heme; Humans; Light; Lovastatin; Omeprazole; Oxidation-Reduction; Photosensitizing Agents; Protein Structure, Tertiary; Simvastatin | 2015 |
High-resolution continuum source graphite furnace atomic absorption spectrometry for screening elemental impurities in drugs to adhere to the new international guidelines.
Topics: Graphite; Losartan; Metals, Heavy; Omeprazole; Simvastatin; Spectrophotometry, Atomic | 2019 |
Simulating the Impact of Elevated Levels of Interleukin-6 on the Pharmacokinetics of Various CYP450 Substrates in Patients with Neuromyelitis Optica or Neuromyelitis Optica Spectrum Disorders in Different Ethnic Populations.
Topics: Administration, Oral; Adult; Caffeine; Clinical Trials as Topic; Computer Simulation; Cytochrome P-450 Enzyme System; Dextromethorphan; Down-Regulation; Drug Development; Drug Interactions; Female; Humans; Interleukin-6; Male; Midazolam; Middle Aged; Models, Biological; Neuromyelitis Optica; Omeprazole; Rare Diseases; Serum Albumin, Human; Simvastatin; Warfarin | 2019 |
Diazepam, metformin, omeprazole and simvastatin: a full discussion of individual and mixture acute toxicity.
Topics: Aliivibrio fischeri; Diazepam; Metformin; Omeprazole; Simvastatin; Toxicity Tests, Acute | 2020 |
Oral Manifestations of Commonly Prescribed Drugs.
Topics: Albuterol; Amlodipine; Anticonvulsants; Antihypertensive Agents; Atorvastatin; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bronchodilator Agents; Deprescriptions; Drug Hypersensitivity; Fluorides; Gingival Overgrowth; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperpigmentation; Hypoglycemic Agents; Lisinopril; Losartan; Metformin; Metoprolol; Mouth Diseases; Omeprazole; Oral Hygiene; Proton Pump Inhibitors; Simvastatin; Thyroxine; Toothpastes; Xerostomia | 2020 |
Medicine-Induced Acute Kidney Injury Findings from Spontaneous Reporting Systems, Sequence Symmetry Analysis and a Case-Control Study with a Focus on Medicines Used in Primary Care.
Topics: Acute Kidney Injury; Adverse Drug Reaction Reporting Systems; Amlodipine; Amphotericin B; Australia; Case-Control Studies; Ciprofloxacin; Diclofenac; Furosemide; Humans; Ibuprofen; Metformin; Naproxen; Omeprazole; Primary Health Care; Ramipril; Simvastatin; Spironolactone; Sulfamethoxazole; Telmisartan; Trimethoprim; Valacyclovir; Zoledronic Acid | 2022 |